Clinical Trial TitleDrug Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
National Clinical Trial Number:NCT04674969
Clinical Trial Protocol Description:
Collection of Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BCS) drug eluting devices for the treatment of lesions locations in the peripheral vasculature. Devices include any commercially available Boston Scientific drug-eluting device marketed for the treatment of lesions in the peripheral vasculature.
Initial primary interest includes: ELUVIA Drug-Eluting Vascular Stent System, Ranger Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Are 18 years of age or older.
- Provide written informed consent (patient data release-form).
- Have use of any commercially available Boston Scientific drug-eluting device marketed for the treatment of lesions in the peripheral vasculature and specified in the Registry Enrollment Guides.
You will be excluded from the study if any of the following criteria apply to you:
- Have a life expectancy that is less than one year.
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.